New treatment approach for Alzheimer's disease using a small molecule
Official title: SMALL MOLECULE THERAPEUTIC FOR ALZHEIMER'S DISEASE
Funded at Somatolynk, INC. · NIH-10695624 · Data updated 2026-11-12
This study is working on a new medication for Alzheimer's disease that aims to help the brain break down harmful proteins and improve thinking skills, with the hope that it can slow down the progression of the disease and offer patients a better quality of life.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Somatolynk, INC. NIH-funded |
| Lab location | 1 site (Edwardsville, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $499,592 |
| NIH project number | 1R41AG080914-01A1 |
| Project ID | NIH-10695624 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease, particularly those in the early to moderate stages of the condition.
✕Less likely to help
Patients with advanced Alzheimer's disease or those with other forms of dementia may not benefit from this research.
What this research studies
This research focuses on developing a new small molecule therapeutic aimed at treating Alzheimer's disease by targeting the somatostatin receptor-4 (SSTR4) in the brain. The approach involves designing and screening compounds that can enhance the metabolism of amyloid-beta, a key factor in Alzheimer's pathology, while also improving cognitive function. The research employs advanced computer-aided drug design and an iterative optimization process to identify the most promising candidates for further development and eventual clinical trials. Patients may benefit from a novel treatment option that could slow disease progression and improve cognitive abilities.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option that may slow the progression of Alzheimer's disease and enhance cognitive function in patients.
How similar studies have gone: While targeting SSTR4 is a novel approach, similar strategies in Alzheimer's research have shown promise, indicating potential for success.
Where this research is happening
-
Somatolynk, INC.
Edwardsville, United States Active
Researchers
- Principal investigator: Witt, Ken — Somatolynk, INC.
- Study coordinator: Witt, Ken
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.